Back grey_arrow_rt.gif
 
 
Melanoma Survival Benefit Called 'Astounding' - full text publication below
 
 
  Download the PDF here
 
MedPage Today
Published: June 05, 2011
 
CHICAGO -- Patients with metastatic melanoma had an "astounding" 63% reduction in the risk of death when treated with an investigational agent that targets a mutation found in about half of the tumors, data from a large international trial showed.
 
Treatment with the BRAF inhibitor vemurafenib improved progression-free survival (PFS) by 74%. Analysis of six-month overall survival (OS) showed a 20% absolute difference between patients treated with vemurafenib versus dacarbazine.
 
Though follow up is brief, the results already make a case for vemurafenib as the comparator for future trials of new agents for advanced melanoma, Paul. B. Chapman, MD, of Memorial Sloan-Kettering Cancer Center in New York City, said at the American Society of Clinical Oncology (ASCO) meeting.
 
"The median follow up was only three months, yet the hazard ratio for death was 0.37 in favor of vemurafenib," Chapman said in an interview with MedPage Today. "That's an astounding difference that is almost never seen in oncology trials."
 
Action Points
 
* Explain that patients with metastatic melanoma had an impressive 63% reduction in the risk of death when treated with an investigational agent, the BRAF inhibitor vemurafenib, that targets a mutation found in about half of the tumors.
 
* Note that vemurafenib was well tolerated, with the most common adverse events being cutaneous events (including some secondary skin cancers), arthralgia, fatigue, and photosensitivity.
 
From 40% to 60% of cutaneous melanomas have BRAF mutations that activate downstream signaling through the MAP kinase pathway. About 90% of the mutations involve a specific substitution at codon 600 (BRAF V600E), Chapman and coauthors wrote in an article simultaneously published online in the New England Journal of Medicine.
 
Preclinical studies showed the vemurafenib exhibited marked inhibition of melanoma cell lines with the BRAF V600E mutations, but not cells with wild-type BRAF. Phase I-II clinical studies provided corroborating evidence of vemurafenib's activity in BRAF-mutated melanoma, leading to an international phase III clinical trial conducted at 104 centers in 12 countries.
 
Investigators randomized 675 patients with the BRAF V600 mutation to oral vemurafenib or to intravenous dacarbazine. The primary endpoint was OS. The last patients were enrolled in December 2010, and a planned interim analysis occurred in January.
 
The interim analysis showed a significant reduction in the hazard ratio (HR) for death among patients treated with vemurafenib (P<0.001). Subgroup analysis revealed a consistent effect of vemurafenib on survival across all prespecified subgroups.
 
Evaluation of PFS in 549 patients yielded an HR of 0.26 for the vemurafenib arm versus dacarbazine (P<0.001). The median PFS was 5.3 months with vemurafenib and 1.6 months for dacarbazine.
 
At the time of the interim analysis, too few patients had been followed beyond seven months to permit reliable determination of survival curves. However, the vemurafenib group had a six-month OS of 84% compared with 64% in the dacarbazine arm.
 
Investigators could assess tumor response in 439 (65%) patients followed for at least 14 weeks before enrollment ended. Most patients in the vemurafenib arm had a detectable decrease in tumor size, said Chapman, and 48% had a confirmed objective response, including two complete responses.
 
In contrast, the dacarbazine group had an objective response rate of 5% (P<0.001).
 
Overall, vemurafenib was well tolerated. The most common adverse events associated with the investigational agent were cutaneous events (including some secondary skin cancers), arthralgia, fatigue, and photosensitivity. Chapman said the secondary skin cancers included some squamous-cell lesions, all of which were excised without complications.
 
Dose interruption or modification was required in 38% of vemurafenib-treated patients.
 
No unexpected adverse events occurred in the dacarbazine group. The most common severe toxicities were fatigue, nausea, vomiting, and neutropenia.
 
Results of the trial constitute a major shift in clinical concepts related to melanoma, Marc S. Ernstoff, MD, said in an editorial that accompanied the NEJM article.
 
"The new understanding of molecular pathways changes the way we classify melanomas and influences therapy," said Ernstoff, of Dartmouth Medical School in Hanover, N.H. "The development of vemurafenib is an example of the translation of these concepts into clinical practice."
 
Inhibition of BRAF V600E carries several potential long-term health consequences, Ernstoff noted. One potential consequence is paradoxical stimulation of MAP kinase-mediated in wild-type BRAF cells, possibly the underlying mechanisms for the secondary nonmelanoma skin cancers observed in the vemurafenib arm.
 
Ernstoff also noted that the results of the vemurafenib trial compare favorably with those of other targeted therapies approved for treatment of metastatic melanoma. Interleukin-2 achieves objective responses in about 16% of patients, including complete responses in 6%. Ipilimumab (Yervoy) treatment has been associated with a median PFS of 11 weeks and an objective response rate of 7%.
 
The study was supported by F. Hoffman-LaRoche/Genentech.
 
Chapman disclosed relationships with F. Hoffmann-LaRoche/Genentech. Several coauthors disclosed relationships with Roche.
 
Investigators included employees of Genentech and F. Hoffmann-LaRoche.
 
Ernstoff had no relevant disclosures.
 
Primary source: New England Journal of Medicine
Source reference:
Chapman PB, et al "Improved survival with vemurafenib in melanoma with BRAF V600E mutation" N Engl J Med 2011;doi:10.1056/NEJMoa1103782.
 
Additional source: New England Journal of Medicine
Source reference:
Ernstoff MS "Been there, not done that -- Melanoma in the age of molecular therapy" N Engl J Med 2011;doi:10.1056/NEJMe1105792.
 
-----------------------------------
 
Original Article
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation - pdf attached
 
Download the PDF here
 
Paul B. Chapman, M.D., Axel Hauschild, M.D., Caroline Robert, M.D., Ph.D., John B. Haanen, M.D., Paolo Ascierto, M.D., James Larkin, M.D., Reinhard Dummer, M.D., Claus Garbe, M.D., Alessandro Testori, M.D., Michele Maio, M.D., David Hogg, M.D., Paul Lorigan, M.D., Celeste Lebbe, M.D., Thomas Jouary, M.D., Dirk Schadendorf, M.D., Antoni Ribas, M.D., Steven J. O'Day, M.D., Jeffrey A. Sosman, M.D., John M. Kirkwood, M.D., Alexander M.M. Eggermont, M.D., Ph.D., Brigitte Dreno, M.D., Ph.D., Keith Nolop, M.D., Jiang Li, Ph.D., Betty Nelson, M.A., Jeannie Hou, M.D., Richard J. Lee, M.D., Keith T. Flaherty, M.D., and Grant A. McArthur, M.B., B.S., Ph.D. for the BRIM-3 Study Group
 
June 5, 2011 (10.1056/NEJMoa1103782)
 
Abstract
 
Background: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.
 
Methods: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths.
 
Results: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.
 
Conclusions: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.)
 
Discussion
 
In our study, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of tumor progression in patients with previously untreated, unresectable stage IIIC or stage IV melanoma with the BRAF V600E mutation, as compared with dacarbazine. Benefit was seen in all subgroups of patients who were included in the analysis, including patients with stage M1c disease or an elevated lactate dehydrogenase level, both of which are associated with particularly poor prognoses.
 
Recently, ipilimumab, an anti-CTLA4 antibody, was shown to improve overall survival in patients with metastatic melanoma, as compared with a peptide vaccine, although there was only a modest effect on rates of response and progression-free survival.8 The use of ipilimumab combined with dacarbazine has also been associated with improved rates of survival over dacarbazine alone.9
 
Overall, 48% of the patients who were treated with vemurafenib met the criteria for a confirmed response, although most patients had some tumor shrinkage. This finding was consistent with the confirmed response rates seen in the phase 1 extension cohort15 and in a recent phase 2 trial involving previously treated patients.16 Furthermore, 4 of 10 patients with the BRAF V600K mutation had a response to vemurafenib, indicating that melanomas with this variant are also sensitive to vemurafenib.
 
The confirmed response rate in the dacarbazine cohort was 5%, which is slightly lower than that in recent phase 3 trials.4-7 Our study was a randomized trial comparing vemurafenib with dacarbazine in which only patients with BRAF-mutated melanomas were treated. Recent studies have raised the possibility that melanomas with the BRAF V600E mutation are more aggressive18,19 and less sensitive to chemotherapy18,20 than BRAF wild-type melanomas. Also, 48 patients (14%) in the dacarbazine group (29 of whom were available for evaluation in this report) did not receive any treatment, most commonly because the patient withdrew consent (Fig. A in the Supplementary Appendix). Patients receiving vemurafenib reported relatively few grade 3 or worse adverse events. Other than cutaneous squamous-cell carcinoma and keratoacanthomas, the most common drug-related grade 3 (or worse) toxic effects were rash, arthralgias, photosensitivity, and fatigue. Overall, 38% of the patients receiving vemurafenib required dose modification because of adverse events.
 
Among patients treated with vemurafenib, 18% were reported to have at least one squamous-cell carcinoma of the skin or keratoacanthoma. These lesions were simply excised, and none required dose modification of vemurafenib. These rates are slightly lower than those reported in the phase 1 and 2 trials of vemurafenib,15,16 probably as a result of shorter follow-up in our study. Cutaneous squamous-cell cancer and keratoacanthomas have also been seen in patients treated with sorafenib,21,22 another compound with inhibitory activity against RAF kinases. No other secondary neoplasia was observed in the patients in our study.
 
The mechanism of the induction of cutaneous neoplasia is under investigation, but it is speculated to involve the activating effect of vemurafenib on preneoplastic cells in which wild-type BRAF is further primed by upstream pathway activation. Several investigators have shown that vemurafenib and other inhibitors of RAF kinases can potentiate the activity of the MAPK pathway in cells with wild-type BRAF.23-25 This finding might explain the favorable therapeutic index of vemurafenib in patients who have melanoma with the BRAF V600E mutation but also suggests that vemurafenib could accelerate the growth of some tumors with wild-type BRAF.
 
An important, related ongoing effort by many research groups is to clarify how melanomas become resistant to vemurafenib. Initial studies from several groups have indicated that the MAPK pathway is reactivated in resistant tumors.26-28 Although the precise mechanisms of reactivation are still being investigated, gatekeeper mutations in BRAF, which would prevent vemurafenib from binding BRAF, have not been observed.
 
Our results show that single-agent vemurafenib improved the rates of response and of both progression-free and overall survival, as compared with dacarbazine, in patients with metastatic melanoma with the BRAF V600E mutation. These findings provide a solid foundation for the development of future combination therapies.
 
Supported by Hoffmann-La Roche.
 
Results
 
Patients and Treatments

 
A total of 118 patients had died at the time of the interim analysis. The data and safety monitoring board determined that both the overall survival and progression-free survival end points had met the prespecified criteria for statistical significance in favor of vemurafenib. The board recommended that patients in the dacarbazine group be allowed to cross over to receive vemurafenib, and the protocol was amended accordingly on January 14, 2011. Median follow-up for the interim analysis was 3.8 months for patients in the vemurafenib group and 2.3 months for those in the dacarbazine group.
 
Efficacy
 
A total of 672 patients were evaluated for overall survival. The hazard ratio for death in the vemurafenib group was 0.37 (95% confidence interval [CI], 0.26 to 0.55; P<0.001) (Figure 1AFigure 1Overall Survival.). The survival benefit in the vemurafenib group was observed in each prespecified subgroup, according to age, sex, ECOG performance status, tumor stage, lactate dehydrogenase level, and geographic region (Figure 1B). At the time of the interim analysis, there were an inadequate number of patients in follow-up beyond 7 months in either study group to provide reliable Kaplan-Meier estimates of the survival curves.17 At 6 months, overall survival was 84% (95% CI, 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. Further follow-up is required.
 
Progression-free survival could be evaluated in 549 patients. The hazard ratio for tumor progression in the vemurafenib group was 0.26 (95% CI, 0.20 to 0.33; P<0.001) (Figure 2AFigure 2Progression-free Survival.). The estimated median progression-free survival was 5.3 months in the vemurafenib group and 1.6 months in the dacarbazine group. Superior progression-free survival with vemurafenib over dacarbazine was observed in all subgroups that were analyzed (Figure 2B).
 
A total of 439 patients (65%) could be evaluated for tumor response on the basis of having undergone randomization at least 14 weeks before the clinical cutoff date of December 30, 2010. In the vemurafenib group, most patients had a detectable decrease in tumor size (Figure 3AFigure 3Best Tumor Response for Each Patient.), and 106 of 219 patients (48%; 95% CI, 42 to 55) had a confirmed objective response (including 2 patients with a complete response and 104 with a partial response), with a median time to response of 1.45 months. Ten patients in the vemurafenib group were later found to have BRAF V600K mutations; of these patients, 4 had a partial response (40%). In the dacarbazine group, a minority of patients had a detectable decrease in tumor size (Figure 3B), and only 12 of 220 patients (5%; 95% CI, 3 to 9) met the criteria for a confirmed response (all partial responses), with a median time to response of 2.7 months. The difference in confirmed response rates between the two study groups (48% vs. 5%) was highly significant (P<0.001 by the chi-square test).
 
Adverse Events
 
A total of 618 patients (92%) underwent at least one assessment as of the clinical cutoff date and were evaluated for toxic effects. Adverse events of grade 2 or more that were reported in more than 5% of the patients in either study group are shown in Table 2Table 2Adverse Events in 618 Patients.; adverse events of any grade that were reported in more than 5% of the patients are shown in Table A in the Supplementary Appendix. The most common adverse events in the vemurafenib group were cutaneous events, arthralgia, and fatigue; photosensitivity skin reactions of grade 2 or 3 were seen in 12% of the patients, with grade 3 reactions characterized by blistering that often could be prevented with sunblock. As expected, the most common severe toxic effects in the dacarbazine group were fatigue, nausea, vomiting, and neutropenia. Adverse events led to dose modification or interruption in 129 of 336 patients (38%) in the vemurafenib group and in 44 of 282 patients (16%) in the dacarbazine group.
 
In the vemurafenib group, a cutaneous squamous-cell carcinoma, keratoacanthoma, or both developed in 61 patients (18%). All lesions were treated by simple excision. Pathological analyses of skin-biopsy specimens from these patients are currently being performed by an independent dermatology working group.
 
Methods
 
Patients

 
All patients in our study had unresectable, previously untreated stage IIIC or stage IV melanoma that tested positive for the BRAF V600E mutation on real-time polymerase-chain-reaction assay (Cobas 4800 BRAF V600 Mutation Test, Roche Molecular Systems). The test was performed at one of five central laboratories in the United States, Germany, and Australia. In approximately one third of the patients, BRAF was sequenced retrospectively by Sanger and 454 sequencing at a central laboratory. Other inclusion criteria were age of 18 years or older, a life expectancy of 3 months or longer, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (fully active and able to carry on all performance without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), and adequate hematologic, hepatic, and renal function. Patients were excluded if they a history of cancer within the past 5 years (except for basal- or squamous-cell carcinoma of the skin or carcinoma of the cervix) or metastases to the central nervous system, unless such metastases had been definitively treated more than 3 months previously with no progression and no requirement for continued glucocorticoid therapy. Concomitant treatment with any other anticancer therapy was not allowed.
 
The protocol was approved by the institutional review board at each participating institution and was conducted in accordance with the ethical principles of the Declaration of Helsinki and within the Good Clinical Practice guidelines, as defined by the International Conference on Harmonization. All patients provided written informed consent before enrollment.
 
Study Design and Treatment
 
From January 2010 through December 2010, a total of 2107 patients underwent screening at 104 centers in 12 countries worldwide. The most common reason for screening failure was a negative test for the BRAF V600 mutation. A total of 675 patients were randomly assigned in a 1:1 ratio to receive either vemurafenib (at a dose of 960 mg twice daily orally) or dacarbazine (at a dose of 1000 mg per square meter of body-surface area by intravenous infusion every 3 weeks) (Fig. A in the Supplementary Appendix, available with the full text of this article at NEJM.org). These patients included 20 with non-V600E mutations (19 with V600K and 1 with V600D), as identified on Sanger and 454 sequencing. Baseline characteristics of the patients were well balanced (Table 1Table 1Baseline Demographic and Clinical Characteristics of Patients in the Intention-to-Treat Population.).
 
Study patients were stratified according to American Joint Committee on Cancer stage (IIIC, M1a, M1b, or M1c), ECOG performance status (0 or 1), geographic region (North America, Western Europe, Australia or New Zealand, or other region), and serum lactate dehydrogenase level (normal or elevated).
 
Dose reductions for both vemurafenib and dacarbazine were prespecified for intolerable grade 2 toxic effects or worse. The development of cutaneous squamous-cell carcinoma did not require dose modification. The administration of vemurafenib was interrupted until the resolution of the toxic effect to at least grade 1 and restarted at 720 mg twice daily (480 mg twice daily for grade 4 events), with a dose reduction to 480 mg twice daily if the toxic effects recurred. If the toxic effect did not improve to grade 1 or lower or recurred at the 480-mg twice-daily dose, treatment was discontinued permanently. The administration of dacarbazine was interrupted for grade 3 or 4 toxic effects and could be restarted on recovery within 1 week to grade 1 (at full dose) or grade 2 (at 75% dose) or at 75% dose for grade 4 neutropenia or febrile neutropenia. A second dose reduction was allowed, if needed. Antiemetics and granulocyte colony-stimulating factor were administered according to standards at each study center. Treatment was discontinued on disease progression unless continued treatment was in the best interest of the patient in the judgment of the investigator and the sponsor.
 
Assessments
 
At baseline, patients underwent computed tomography with contrast material or magnetic resonance imaging of the brain, chest, abdomen, pelvis, and other anatomical regions, as clinically indicated. Patients also underwent physical and dermatologic examinations and electrocardiography. Patients were examined every 3 weeks; tumor assessments were performed at baseline, at weeks 6 and 12, and every 9 weeks thereafter. Tumor responses were determined by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Electrocardiograms were repeated every other cycle. Blood counts, biochemical analyses, and measurements of lactate dehydrogenase levels were performed at each visit.
 
Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.0. Monitoring of adverse events continued for up to 28 days after the last dose of a study drug had been administered or until any ongoing event resolved or stabilized. An independent data and safety monitoring board provided oversight and evaluated interim results on efficacy data.
 
Study Oversight
 
The trial was designed jointly by the senior academic authors and representatives of the sponsor, Hoffmann-La Roche. Data were collected by the sponsor and analyzed in collaboration with the senior academic authors, who vouch for the completeness and accuracy of the data and analyses and for the conformance of this report to the protocol, as amended. The corresponding academic author prepared an initial draft of the manuscript in collaboration with the sponsor. All the authors contributed to subsequent drafts and made the decision to submit the manuscript for publication. The protocol and statistical analysis plan are available at NEJM.org.
 
Statistical Analysis
 
The original primary end point was the rate of overall survival. The statistical plan was revised in October 2010 on the basis of phase 1 and 2 efficacy and safety results and after consultation with global regulatory authorities. Under the revised plan, the rates of overall survival and progression-free survival were coprimary end points. The final analysis was planned after 196 deaths, and an interim analysis was planned after 50% of the projected deaths had occurred (Pocock boundary, P≤0.028 at the interim analysis and P≤0.0247 at the final analysis by the log-rank test). According to the revised plan, the final analysis of progression-free survival would be performed at the time of the interim analysis of overall survival. Secondary end points included the confirmed response rate, duration of response, and time to response.
 
The trial was designed for 680 patients to be randomly assigned to receive either vemurafenib or dacarbazine. The trial had a power of 80% to detect a hazard ratio of 0.65 for overall survival with an alpha level of 0.045 (an increase in median survival from 8 months for dacarbazine to 12.3 months for vemurafenib) and a power of 90% to detect a hazard ratio of 0.55 for progression-free survival with an alpha level of 0.005 (an increase in median survival from 2.5 months for dacarbazine to 4.5 months for vemurafenib). Survival was defined as the time from randomization to death from any cause. Progression-free survival was the time from randomization to documented disease progression or death. We used a two-sided unstratified log-rank test to compare survival rates in the two study groups. Hazard ratios for treatment with vemurafenib, as compared with dacarbazine, were estimated with the use of unstratified Cox regression. We estimated event-time distributions using the Kaplan-Meier method. All reported P values are two-sided, and confidence intervals are at the 95% level. Descriptive statistics are used for adverse events.
 
This report is based on data as of December 30, 2010. Efficacy analyses were performed in the intention-to-treat population. In order to ensure adequate follow-up for each efficacy end point, patients could be evaluated for the analysis of overall survival, progression-free survival, and confirmed response if they had undergone randomization at least 2, 9, and 14 weeks, respectively, before the cutoff date. The safety analysis was performed in all patients who received a study drug and who had undergone at least one assessment during the study.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org